Skip to content
value.today

Vedantra Pharmaceuticals, Inc.

Total raised
$73 M
6 rounds on record
Latest round
$22 M
May 2022
First round on record
Jul 2012
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vedantra Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2022$22 MNo. 6$10 to $50 million

Vedantra Pharmaceuticals, Inc.: Raise no. 6, May 2022

Investors in this round

7 investors had bought by the notice of Nov 2, 2022: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$22 M of $50 M offered; $28 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$989,794
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Annette Matthies · Executive Officer
  • Christopher Haqq · Executive Officer
  • Daniel Geffken · Executive Officer, Director
  • Robert Connelly · Executive Officer, Director
  • Assaf Segal · Director
  • Carol Ashe · Director
  • Daphne Karydas · Director
  • Julian Adams · Director
  • Robert Ruffolo · Director
  • Yekaterina Chudnovsky · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Finalis Securities LLC (CRD 305908) · New York, New YorkSold in all US states

Signed by Robert Connelly, Chief Executive Officer. Newest notice filed Nov 2, 2022. Read the notice at the SEC.

equitySEC
Jun 2020$6 MNo. 5$2 to $10 million

Vedantra Pharmaceuticals, Inc.: Raise no. 5, Jun 2020

Investors in this round

49 investors had bought by the notice of Jul 15, 2020: 49 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $30 M offered; $24 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series B Preferred Stock. The Issuer may, in its sole discretion, waive the minimum investment of $50,000.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$608,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Haqq · Executive Officer · Dr. Haqq is an Executive Vice President, Head of Research and Development and the Chief Medical Officer of the Issuer.
  • Daniel Geffken · Executive Officer, Director · Mr. Geffken is the Chief Financial Officer of the Issuer.
  • Robert Connelly · Executive Officer, Director · Mr. Connelly is the Chief Executive Officer of the Issuer.
  • Isaac Kohlberg · Director
  • Julian Adams · Director · Dr. Adams is the Chairman of the Board of Directors of the Issuer.
  • Robert Ruffolo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “The persons named in Item 12 receive a 10% commission consisting of cash and warrants to purchase shares of the common stock of the Issuer.”

Signed by Robert Connelly, Chief Executive Officer of the Issuer. Newest notice filed Jul 15, 2020. Read the notice at the SEC.

equitySEC
Feb 2020$8 MNo. 4$2 to $10 million

Vedantra Pharmaceuticals, Inc.: Raise no. 4, Feb 2020

Investors in this round

108 investors had bought by the notice of Mar 13, 2020: 108 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Common Stock; Series B Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$841,180
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Geffken · Executive Officer, Director · Mr. Geffken is the Chief Financial Officer of the Issuer.
  • Julian Adams · Executive Officer, Director · Dr. Adams is the Executive Chairman of the Board of Directors of the Issuer.
  • Robert Connelly · Executive Officer, Director · Mr. Connelly is the Chief Executive Officer of the Issuer.
  • Isaac Kohlberg · Director
  • Robert Ruffolo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “The persons named in Item 12 received a 10% commission consisting of cash and warrants.”

Signed by Robert Connelly, Chief Executive Officer of the Issuer. Newest notice filed Mar 13, 2020. Read the notice at the SEC.

equitySEC
Sep 2019$7 MNo. 3$2 to $10 million

Vedantra Pharmaceuticals, Inc.: Raise no. 3, Sep 2019

Investors in this round

2 investors had bought by the notice of Oct 15, 2019: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Series B Preferred Stock and Warrants.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$700,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Geffken · Executive Officer, Director · Mr. Geffken is the Chief Financial Officer of the Issuer.
  • Julian Adams · Director, Executive Officer · Mr. Adams is the Executive Chairman of the Board of Directors of the Issuer.
  • Robert Connelly · Executive Officer, Director · Mr. Connelly is the Chief Executive Officer of the Issuer.
  • Frank Haluska · Director
  • Isaac Kohlberg · Director
  • Robert Ruffolo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Merchant Capital · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “The persons named in Item 12 may receive a commission from the gross proceeds of the offering.”

Signed by Robert Connelly, Chief Executive Officer of the Issuer. Newest notice filed Oct 15, 2019. Read the notice at the SEC.

equity, optionsSEC
Aug 2018$26 MNo. 2$10 to $50 million

Vedantra Pharmaceuticals, Inc.: Raise no. 2, Aug 2018

Investors in this round

137 investors had bought by the notice of Sep 14, 2018: 137 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M of $36 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Series B Preferred Stock and Warrants. The Issuer and the Placement Agent may mutually agree to accept lesser amounts than the minimum investment of $50,000.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$525,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Geffken · Executive Officer, Director · Mr. Geffken is the Chief Financial Officer of the Issuer.
  • Frank Haluska · Director
  • Isaac Blech · Director
  • Isaac Kohlberg · Director
  • Julian Adams · Director · Mr. Adams is the Executive Chairman of the Board of Directors of the Issuer.
  • William Koster · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Merchant Capital · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “The persons named in Item 12 will receive a commission of 10% of the gross proceeds of the offering and a percentage of the gross proceeds realized from the conversion of the promissory notes.”
  • On the amounts: “Includes value of convertible notes and interest on such notes.”

Signed by Daniel Geffken, Chief Financial Officer of the Issuer. Newest notice filed Sep 14, 2018. Read the notice at the SEC.

equity, optionsSEC
Jul 2012$3 MNo. 1$2 to $10 million

Vedantra Pharmaceuticals, Inc.: Raise no. 1, Jul 2012

Investors in this round

1 investor had bought by the notice of Jul 31, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan Shaw · Executive Officer, Director, Promoter
  • Ben Bronstein · Director
  • Daniel Behr · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series A Convertible Redeemable Preferred Stock”

Signed by Alan Shaw, Chief Executive Officer. Newest notice filed Jul 31, 2012. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vedantra Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2022).

    SEC Form D · Nov 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2022

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Vedantra Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vedantra Pharmaceuticals, Inc.
NameRoleNamed in
Annette MatthiesExecutive officerNov 2022
Christopher HaqqExecutive officerNov 2022
Daniel GeffkenExecutive officerNov 2022
Robert ConnellyExecutive officerNov 2022
Julian AdamsDr. Adams is the Executive Chairman of the Board of Directors of the Issuer.Mar 2020
Alan ShawExecutive officerJul 2012
Assaf SegalDirectorNov 2022
Carol AsheDirectorNov 2022
Daniel GeffkenDirectorNov 2022
Daphne KarydasDirectorNov 2022
Julian AdamsDirectorNov 2022
Robert ConnellyDirectorNov 2022
Robert RuffoloDirectorNov 2022
Yekaterina ChudnovskyDirectorNov 2022
Isaac KohlbergDirectorJul 2020
Frank HaluskaDirectorOct 2019
Isaac BlechDirectorSep 2018
William KosterDirectorSep 2018
Alan ShawDirectorJul 2012
Ben BronsteinDirectorJul 2012
Daniel BehrDirectorJul 2012
Alan ShawPromoterJul 2012